New hope for painful skin bumps: experimental drug NAV-240 enters Mid-Stage trial
Disease control
Recruiting now
This study tests whether NAV-240 can reduce painful skin bumps and draining tunnels in people with moderate-to-severe hidradenitis suppurativa (HS). About 150 adults will receive either NAV-240 or a placebo through an IV drip. The main goal is to see if NAV-240 leads to a 75% red…
Phase: PHASE2 • Sponsor: Navigator Medicines, Inc. • Aim: Disease control
Last updated May 11, 2026 20:40 UTC